---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-003658"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T05:00:20.840248+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# COMPASS Pathways reports FY2021 net loss $71.7M; positive phase IIb TRD results, FDA meeting in April

## Summary
- Net loss for FY2021 was $71.7M ($1.79 loss per share), vs $60.3M in FY2020; Q4 net loss $25.7M.
- Cash balance $273.2M at year-end 2021, up from $190.3M in 2020; well-capitalized for phase III.
- Positive phase IIb trial of COMP360 psilocybin for TRD: rapid and sustained response at 25mg dose.
- End-of-phase II meeting with FDA scheduled for late April 2022; phase III expected H2 2022.
- New senior executives: Dr Guy Goodwin (CMO), Mike Falvey (CFO), Matt Owens (General Counsel).

## SEC filing metadata
- accession: 0001628280-22-003658
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000162828022003658/0001628280-22-003658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000162828022003658/cmps-20220224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-003658
- JSON: https://secwatch.observer/filing/0001628280-22-003658.json
- Plain text: https://secwatch.observer/filing/0001628280-22-003658.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.